Email updates

Keep up to date with the latest news and content from BMC Proceedings and BioMed Central.

This article is part of the supplement: International Conference for Healthcare and Medical Students 2012

Open Access Open Badges Oral presentation

A novel assay of thrombotic risk

Fahad Buskandar*, M Alobaidly and N Moran

Author Affiliations

Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

For all author emails, please log on.

BMC Proceedings 2013, 7(Suppl 1):O4  doi:10.1186/1753-6561-7-S1-O4

The electronic version of this article is the complete one and can be found online at:

Published:30 January 2013

© 2013 Buskandar et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


It is widely believed that platelet responsiveness can be used as a marker for assessing thrombotic risk in patients. Therefore, there have been many attempts to develop suitable assays for quantifying platelet responses in clinical samples 1. Platelet aggregometry is widely used, but is limited in its ability to assess platelet hyper-responsiveness. In order to develop a better assay of thrombotic risk, we use a novel assay to evaluate platelet secretion of adenosine triphosphate & diphosphate (ATP/ADP) in response to various agonists. This assay measures both the maximal amount of adenine nucleotides released by a range of platelet activators and the potency of each activator.


To determine the reproducibility of this assay, we assessed 4 healthy female subjects on 3 separate occasions. 10mls of blood was drawn from subjects who had abstained from medication for the previous 12 days. Platelet ATP/ADP secretion was assessed in a 96 well assays as previously described 2. Briefly, platelet secretion is assessed in response to increasing doses of platelet agonists (Thrombin receptor activating peptide: TRAP 0.1-32µM; Collagen related peptide: CRP 0.05-100µg/ml). Released ATP/ADP is measured using firefly luciferase (Chronolume Corp). Data are expressed as nmoles ATP/ADP secreted per 106 platelets. Dose-response curves are constructed and analysed using GraphPad Prism 5.0.


The maximal amount of ATP/ADP released is similar for both agonists tested (1.94±0.25 and 2.12±0.28 nmoles per 106 platelets in response to TRAP and CRP, respectively). However, the potency of responses, measured as EC50 values, differed for the two agonists. For TRAP, the EC50 values were equivalent in all 4 donors (mean EC50 value is 4.84 ±0.30µM; range 4.38-5.57µM). in response to CRP, the potency of the responses were nearly similar for all the donors (EC50 range from 0.37µg/ml to 1.08µg/ml). Nonetheless, there is a high degree of concordance within all samples from any one donor.


Our data demonstrate that individual donors display unique response-parameters which may be used to assess thrombotic risk. In addition, we can conclude that the dose of agonist that causes a half-maximal response is a reliable index of platelet responsiveness.


  1. Harrison P, Mumford A: .

    Semin Thromb Hemost 2009, 35:150-7. OpenURL

  2. Lombardi F, De Chaumont C, Shields DC, Moran1 N: .

    Platelets 2012, 23:7-25. OpenURL